CAR T-Cell III

Unlike my first 2 posts here and here on CAR T-Cells this is an almost serious proposal. It involves more work and expense than current therapy, but does not, as far as I can see add even purely hypothetical risks. The idea is that the problem with CAR T-cell therapy of solid tumors has to do with the original antigen presentation and conversion of the T-Cells from the naive to the memory state. The solution would be to use patient macrophages and incubate the new CAR T-cells with them and lost of added antigen. The macrophages would have to be activated. I think a general Toll like receptor agonist (pattern recognition agonist, inate immunity agonist) such as lipopolysaccharide or RNA or poly GC would do.

It would be best to induce central memory T-cells rather than effector memory T-cells, but I think memory phenotype of either type might do.